证券日报网讯8月27日晚间，华特达因（000915）发布公告称，公司于2025年8月27日召开2025年临时职 工代表大会，经与会职工代表民主选举范智胜先生为公司第十一届董事会职工代表董事。 ...

全国优秀律师事务所 山东众成清泰（济南）律师事务所 关于山东华特达因健康股份有限公司 召开 2025 年第一次临时股东会的 法律意见书 致 山东华特达因健康股份有限公司： 山东众成清泰（济南）律师事务所(以下简称"本所")接受山东 华特达因健康股份有限公司(以下简称"公司")委托，指派高梦影、 宋祥潇律师，根据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、中国证券监督 管理委员会《上市公司股东会规则》(以下简称"《股东会规则》") 等法律、法规、规章和其他规范性文件以及《山东华特达因健康股份 有限公司章程》(以下简称"《公司章程》")的有关规定，就公司召开 2025 年第一次临时股东会(以下简称"本次股东会"或"本次会议") 的召集、召开程序、现场出席会议人员资格、召集人资格、会议表决 程序和表决结果等事宜进行见证，并出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 在本法律意见书中，本所律师仅对本次股东会的召集、召开程序、 出席会议人员资格、召集人资格及会议表决程序、表决结果是否符合 法律、法规、规范性文件及《公司章程》的规定发表意 ...

证券代码：000915 证券简称：华特达因 公告编号：2025-038 山东华特达因健康股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示 7．出席本次会议的股东及股东授权委托代表共 427 名，代表股 份 65,858,632 股，占公司有表决权股份总数的 28.1049％，其中出席 本次现场会议的股东及股东代理人共 3 名，代表股份 51,623,740 股， 1 3．会议的召开方式：现场投票与网络投票相结合。 4．会议召集人：公司董事会。 5．会议主持人：董事长朱效平。 占公司有表决权股份总数的 22.0302％；通过网络投票出席会议的股 东共 424 名，代表股份 14,234,892 股，占公司有表决权股份总数的 6.0747％。 1．本次股东会未出现否决议案的情形。 2．本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1．会议召开的时间：现场会议召开时间为 2025 年 8 月 26 日下 午 14:30；网络投票的时间为 2025 年 8 月 26 日，其中通过深圳证 ...

山东华特达因健康股份有限公司 董事会议事规则 第一条 宗旨 为健全和规范山东华特达因健康股份有限公司（以下简称"公司"或"本公司"） 董事会议事决策程序，保证公司经营、管理工作的顺利进行，根据《中华人民共和国 公司法》、《中华人民共和国证券法》、《上市公司治理准则》等国家有关法律、法 规和《山东华特达因健康股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，并结合本公司的实际情况，制定本规则。 第二条 公司董事会有中长期发展决策权、经理层成员选聘权、经理层成员业绩 考核权、经理层成员薪酬管理权、职工工资分配管理权、重大财务事项管理权等职权。 第三条 董事会对股东会负责，行使以下职权： （八）决定公司内部管理机构的设置； （九）决定聘任或者解聘公司总经理、董事会秘书及其他高级管理人员，并决定 1 （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或者减少注册资本、发行债券或者其他证券及上市方案； （六）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更公司形 式的方案； （七）在 ...

山东华特达因健康股份有限公司 股东会议事规则 第一章 总则 第一条 为规范山东华特达因健康股份有限公司（以下简称"公司"）行为， 保证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称《公司 法》）《中华人民共和国证券法》（以下简称《证券法》）《上市公司股东会 规则》《山东华特达因健康股份有限公司章程》（以下简称《公司章程》）等 的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应 当勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的6个月内举行。临时股东会不定期召开，出现以下 应当召开临时股东会的情形时，临时股东会应当在2个月内召开： （一）董事人数不足《公司法》规定人数或者《公司章程》所定人数的三 分之二时； （二）公司未弥补的亏损达股本总额三分之一时； （三）单独或者合计持有公司百分之十以上股份的 ...

山东华特达因健康股份有限公司 二〇二五年八月二十六日 | | | 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规 范公司的组织和行为，根据《中华人民共和国公司法》（以下简 称《公司法》）、《中华人民共和国证券法》（以下简称《证券 法》）和其他有关规定，制定本章程。 第二条 公司系依照《股份公司规范意见》和其他有关规定 成立的股份有限公司（以下简称"公司"）。 公司是经山东省经济体制改革委员会鲁体改生字[1993]第 224号文批准，于一九九三年六月二十六日以募集方式设立；公 司于一九九六年八月按照国务院国发〔1995〕17号文和山东省 人民政府鲁政发〔1995〕126号文要求，依照《公司法》进行了 规范，得到山东省经济体制改革委员会鲁体改函字（1996）第56 号文确认，并由"山东声乐鞋业（集团）股份有限公司" 更名 为"山东声乐股份有限公司"。经公司股东大会审议通过，2001 年11月 11 日，公司名称由"山东声乐股份有限公司"变更为 "山东山大华特科技股份有限公司"。经公司2020年年度股东大 会审议通过，2021年4月26日，公司名称由"山东山大华特科技 股份有限公司"变更为"山东 ...

Group 1 - The core point of the news is that Huate Dain has experienced a decline in stock price over three consecutive trading days, with a cumulative drop of -0.59% [1] - Huate Dain Health Co., Ltd. is listed on the Shenzhen Stock Exchange with the stock code 000915 [1] - In the second quarter of this year, the Zhaoshang Fund's Zhaoshang Medical Health Industry Stock Fund entered the top ten shareholders of Huate Dain, marking a new investment [1] Group 2 - The Zhaoshang Medical Health Industry Stock Fund has achieved a year-to-date return of 31.18%, ranking 223 out of 979 in its category [2] - The fund's performance over various periods includes a 1-week increase of 1.28%, a 1-month increase of 5.01%, a 3-month increase of 24.50%, a 6-month increase of 25.57%, and a year-to-date increase of 31.189% [2] - The average performance of similar funds for the year is 22.009%, indicating that Zhaoshang's fund has outperformed its peers [2] Group 3 - Li Jiasun, the fund manager of Zhaoshang Medical Health Industry Stock Fund, has a Master's degree in Economics and has been involved in the pharmaceutical industry research since 2008 [3][4] - Li Jiasun has been managing the Zhaoshang Medical Health Industry Stock Fund since January 30, 2015, and has a total management experience of over 10 years [4] - The Zhaoshang Fund Management Co., Ltd. was established in December 2002, with major shareholders being China Merchants Bank and China Merchants Securities [4]

Core Insights - Huate Dain (stock code: 000915) reported a revenue of 1.17 billion yuan for the first half of 2025, representing a year-on-year growth of 1.39% [1][2] - The net profit attributable to shareholders was 337 million yuan, an increase of 1.69% compared to the same period last year [1][2] - The net cash flow from operating activities reached 674 million yuan, showing a significant increase of 61.44% year-on-year [1][2] Financial Performance - Revenue for the reporting period: 1,170,478,273.18 yuan, up from 1,154,413,477.20 yuan, a growth of 1.39% [2] - Net profit attributable to shareholders: 337,467,373.75 yuan, compared to 331,871,287.24 yuan last year, an increase of 1.69% [2] - Net profit after deducting non-recurring gains and losses: 332,340,551.27 yuan, up 4.31% from 318,600,238.57 yuan [2] - Basic and diluted earnings per share: 1.44 yuan, a slight increase of 1.41% from 1.42 yuan [2] - Weighted average return on equity: 10.96%, an increase of 0.15 percentage points from 10.81% [2] Asset Overview - Total assets at the end of the reporting period: 4,596,433,238.58 yuan, down 6.78% from 4,930,936,591.73 yuan at the end of the previous year [2] - Net assets attributable to shareholders: 2,780,455,844.63 yuan, a decrease of 4.51% from 2,911,651,440.88 yuan [2] Business Segments - The primary revenue and profit source for Huate Dain is its subsidiary, Dain Pharmaceutical, which achieved a revenue of 1.15 billion yuan in the first half of 2025, accounting for 98.59% of the company's consolidated revenue [1][2] - Dain Pharmaceutical's key children's products include Yikexin, YDxin, Dain Iron, Dain Calcium, Dain Zinc, and others, with Yikexin being a well-known trademark in China [2] Brand Value and Market Position - In the first half of 2025, Dain Pharmaceutical was listed among the "2025 China Brand 500 Strong" with a brand value of 231.26 billion yuan, and its flagship product Yikexin was valued at 49.82 billion yuan [3] - The company is focused on children's clinical needs and is developing multiple products in respiratory and mental health fields, with four new projects submitted for approval in 2025 [3] Company Background - Established in 1993 and listed on the Shenzhen Stock Exchange in 1999, Huate Dain has a registered capital of 234 million yuan, with Shandong Huate Holding Group as the largest shareholder [3] - The company operates as a national-level comprehensive new drug research and development platform, with several innovation centers dedicated to children's medication [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [6][18]. Core Views - The company achieved a revenue of 1.17 billion yuan in H1 2025, reflecting a year-on-year growth of 1.39%, with a net profit of 337 million yuan, up 1.69% year-on-year. The net profit margin reached a historical high of 28.83% [3][6]. - The company continues to focus on its core pediatric pharmaceutical business, with its subsidiary, Dain Pharmaceutical, contributing 98.6% of the consolidated revenue [3]. - The company has signed an exclusive distribution agreement for Melatonin Granules (Manlejing®), enhancing its pediatric product portfolio and addressing a significant clinical need in the market [4][5]. Financial Performance - In Q2 2025, the company reported a revenue of 554 million yuan, down 4.88% year-on-year, and a net profit of 155 million yuan, down 4.97% year-on-year. The gross margin was 85.19%, a decrease of 2.01 percentage points year-on-year [3]. - The company forecasts revenues of 2.37 billion yuan, 2.64 billion yuan, and 2.94 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 11% for both 2025 and 2026, and 12% for 2027 [6][8]. - The net profit is projected to be 550 million yuan, 610 million yuan, and 682 million yuan for the same years, with growth rates of 7% for 2025, 11% for 2026, and 12% for 2027 [6][8]. Product Development and Market Position - The company's flagship product, "Yikexin Vitamin AD Drops," maintains a high market share and leadership position, while the product matrix continues to expand with new offerings such as Dain Iron and Dain Calcium [5]. - The marketing strategy targeting children aged 0-18 has shown positive results, with significant sales growth in specific product lines [5].

Group 1 - The company, Huate Dain, stated that after obtaining the registration certificate for a new drug, a series of procedures and market access preparations are required before production and sales can commence [2] - The company plans to develop a feasible sales strategy based on market research and disease incidence rates to expedite sales [2]